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Abstract
The increasing availability of personal genomic tests has led to discussions about the validity and
utility of such tests and the balance of benefits and harms. A multidisciplinary workshop was
convened by the National Institutes of Health and the Centers for Disease Control and Prevention to
review the scientific foundation for using personal genomics in risk assessment and disease
prevention and to develop recommendations for targeted research. The clinical validity and utility
of personal genomics is a moving target with rapidly developing discoveries but little translation
research to close the gap between discoveries and health impact. Workshop participants made
recommendations in five domains: (1) developing and applying scientific standards for assessing
personal genomic tests; (2) developing and applying a multidisciplinary research agenda, including
observational studies and clinical trials to fill knowledge gaps in clinical validity and utility; (3)
enhancing credible knowledge synthesis and information dissemination to clinicians and consumers;
(4) linking scientific findings to evidence-based recommendations for use of personal genomics; and
(5) assessing how the concept of personal utility can affect health benefits, costs, and risks by
developing appropriate metrics for evaluation. To fulfill the promise of personal genomics, a rigorous
multidisciplinary research agenda is needed.
Keywords
behavioral sciences; epidemiologic methods; evidence-based medicine; genetics; genetic testing;
genomics; medicine; public health
The accelerated discovery of genes for common diseases fuels expectations that genomic
information will become an integral component of personalized health care and disease
prevention.1,2 Several companies now offer personal genomics (PG) tests directly to
consumers (DTC). For our purposes, we define PG tests as those that provide comprehensive
genetic risk profiles for many diseases or targeted genetic risk profiles for specific conditions
(e.g., breast cancer). Such tests can include single or multiple genes, linked or causative single
nucleotide polymorphisms, functional assays, and full gene or genome sequencing. PG tests
can be requested by a physician or provided DTC.3
DTC marketing of PG tests can bypass the need for clinicians to order and/or interpret genetic
tests, although companies differ in the extent to which they offer genetic counseling, and some
states mandate provider involvement. Some scientists have voiced concerns regarding the
current scientific foundation for the clinical validity (CV) and clinical utility (CU) of PG tests
and the potential impact on our health care system.4 PG tests may lead to a medical testing
“cascade effect” with unwarranted diagnostic, pharmacologic, and surgical interventions.5 The
cascade effect has been well described for various radiology procedures (such as total body
computed tomographic scans). There are also public health concerns regarding costs and
possible patient harms if such cascade effects lead to unfounded preferences for
pharmaceuticals or reduced motivations to pursue healthy lifestyles (see also discussion of
personal utility later). Conversely, others have argued that PG tests can empower consumers
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and their providers in health promotion, as well as early disease detection and management,
making the health care system more proactive.6 The emergence of PG tests coincides with
increasing access and demand for health information.7 The arguments both for and against the
use of PG must be informed by appropriate scientific research on benefits and risks.8
The workshop
To discuss the scientific foundation for using PG tests in risk assessment and disease
prevention, a multidisciplinary workshop was convened by several Institutes of the National
Institutes of Health and the Centers for Disease Control and Prevention. The workshop sought
to enhance dialogue among various stakeholders, identify gaps in knowledge, and suggest
research areas. Multiple viewpoints and disciplines were represented, including industry,
consumer, clinical, epidemiology, genetics, communication, social, and behavioral sciences.
The following questions were discussed using case studies. (1) Is there evidence of public and
provider interest in PG testing? (2) What evidence is needed to determine whether genetic
information from PG tests adds to existing risk algorithms in predicting health outcomes? (3)
What evidence is needed to determine whether PG tests can improve clinical outcomes? (4)
What type of research is needed to determine CV and CU of PG tests? Details of the workshop
can be accessed online.9 Not included in this report are the workshop discussions of government
oversight, policy, and regulation of DTC genetic tests. These issues are also being considered
by various advisory groups such as the Institute of Medicine and the Department of Health and
Human Services' Secretary's Advisory Committee on Genetics, Health, and Society. In
particular, Secretary's Advisory Committee on Genetics, Health, and Society published
recommendations for oversight of genetic tests in 2008.10
A framework for scientific evaluation of personal genomics
The potential utility of PG tests for risk assessment and health improvement can be viewed by
stages of disease natural history and points of intervention (Table 1)11. For primary prevention,
genetic information may inform decision making for minimizing risk exposures, improving
health behaviors and lifestyle factors, or providing prophylactic surgery, chemoprevention, or
other customized interventions. Genetic information also can be useful in early disease
detection (secondary prevention), in targeting treatments (tertiary prevention), and improving
survival and psychosocial outcomes (quaternary prevention). Key assumptions for the
scientific foundation for PG are that risk assessment should be followed by effective and safe
interventions that can reduce morbidity, improve health, or other measurable utility endpoints;
and that genetic information based on the combination of variants across the genome should
be evaluated like other biological markers for screening or risk assessment. Finally, these
assumptions must also be put in the context of well-known principles of population screening,
especially as applied to genetic risk factors for asymptomatic individuals. These principles
include public health importance, knowledge of the natural history of the disorder, availability
of effective interventions, and full considerations of the ethical, legal, and social and policy
issues surrounding these technologies.12
Multidisciplinary translation research is needed to connect gene discovery to improved health
outcomes via four overlapping phases of research, denoted T1 to T4.13 T1 research entails the
development of candidate genetic tests based on discovery, replication, and clinical and
epidemiologic characterization. T2 research involves the evaluation of these tests for validity
and utility and the development of evidence-based recommendations for their use. T3 research
involves evaluating best approaches for diffusion, dissemination, and implementation of tests
into practice. T4 research entails assessing the population impact including effectiveness and
economic value of these tests in real-world settings.
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The evaluation of genetic tests across the four translation research phases has been described
using the ACCE framework (analytic validity, CV, CU, and ethical, legal, and social
implications).14 This framework was formalized by the Evaluation of Genomic Applications
in Practice and Prevention (EGAPP) working group,15 an independent panel that reviews
available data on validity and utility of genomic applications and produces evidence-based
recommendations.16–19 The EGAPP working group adapted the methods of the US Preventive
Services Task Force (USPSTF) for genomic applications. The USPSTF is a long-standing
independent panel that has developed numerous evidence-based recommendations relevant to
clinical preventive services.20 The EGAPP working group developed methods for assessing
genetic tests for different applications (diagnostic, screening, risk assessment, prognostic, and
pharmacogenomics) for both genetic disorders and common diseases. The group is currently
reviewing two topics related to PG tests (Type 2 diabetes and coronary heart disease).21 As
discussed later, issues of CV and CU are qualitatively and quantitatively different for PG tests
designed for risk assessment compared with diagnostic tests for genetic disorders with high
penetrance.
The workshop focused on CV and CU. Participants only briefly covered analytic validity
because current genomic assays have high sensitivity and specificity for measured genetic
variants. However, participants agreed that oversight is still needed to ensure laboratory quality
of tests and the testing process.10 The evaluation of CV and CU is an ongoing and iterative
process that occurs throughout the translation continuum, including evaluating early efficacy
and effectiveness in real-world settings. As discussed recently by Wideroff et al.,22 research
on dissemination, diffusion, effectiveness, and impact should be considered as part of a robust
health services research agenda for genomic technologies.
Establishing clinical validity in personal genomics
The CV of a genetic variant is defined by its relationship with a phenotype or a health outcome,
singly or in combination with other variants and environmental factors. Two steps are needed
in evaluating CV: (1) establishing credible genetic associations and (2) assessing genetic
disease associations in relation to the predictive value, especially vis-à-vis existing risk factors.
Credibility of genetic associations: Replication and knowledge synthesis
Variants identified by candidate gene studies and genome-wide association studies (GWAS)
tend to be common (allele frequencies >5%) with small effect sizes (odds ratios <1.5).23 Many
variants are not known to alter biological function and may be in linkage disequilibrium with
unknown disease-related variants.24 Resequencing is beginning to identify rare potentially
functional mutations that may underlie common variant disease associations.25–27 Currently,
much of the heritability for common diseases is unexplained.23,24 However, we expect the
current landscape to change rapidly as more variants are discovered and gene–gene and gene–
environment interactions are used to refine risk estimates. Population-based case-control and
cohort studies are crucial for establishing credible risk estimates of genetic variants.28,29 In
addition, the cumulative evidence for genetic associations should be rigorously evaluated by
systematic reviews and meta-analyses that determine if differences exist across populations.
30,31
Consensus guidelines for grading cumulative evidence on genetic associations use three
criteria: amount of evidence, replication, and protection from bias.32 The amount of evidence
can be defined by sample size, false discovery rate, or Bayesian credibility.32 Consistency of
replication across different datasets and populations also must be considered (most published
GWAS have built-in replication). Protection from bias can be difficult to determine. Typical
biases include phenotype mis-classification, population stratification, and selective reporting.
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The cumulative assessment of genetic associations in available PG tests is still a moving target.
For example, in a 2008 analysis of genetic associations included in PG tests, Janssens et al.
33 found that of 56 genes tested, 24 (43%) had not been subjected to meta-analyses. For the
remaining 260 meta-analyses, 60 (38%) were nominally statistically significant. The use of
different single nucleotide polymorphisms to assess risk for the same disease has occasionally
resulted in divergent results given to individuals.34–36 Currently, several companies offering
PG tests use genetic risk factors that have been replicated in multiple studies and have worked
together toward industry-wide standards.37–40 However, such standards are still work-in-
progress and not uniformly accepted or applied.
Access to credible and rapidly updated information on genetic associations is difficult to deliver
and urgently needed. One such approach is the HuGE Navigator, an online, continuously
updated database of citations on human genome epidemiology.41 As of June 25, 2009, the
knowledge base contained 43,515 genetic association studies, 1046 meta-analyses, 368
GWAS, 5593 genes, and 2204 disease terms. The HuGE Navigator allows users to view
disease- and gene-centered pages to navigate to online databases (e.g., University of California
at Santa Cruz Genome Browser,42 Gene Tests,43 and PharmGKB44).
Using genetic association in risk assessment and disease prediction
Even if a genetic association is highly credible, how useful is the information for risk
assessment and disease prediction? An important aspect of CV is the degree to which variants
can distinguish between those who will develop an outcome from those who will not. Measures
of sensitivity, specificity, positive predictive value, and negative predictive value are needed.
45 Predictive values depend on the definition and prevalence of the outcome, characteristics of
the tested population, penetrance, and genetic/allelic heterogeneity. Even for predominantly
single gene conditions, such as hereditary breast cancer, heterogeneity can lower the positive
predictive value and therefore the validity of genetic variants.46 Decision analyses for using
absolute risk models to determine appropriate interventions may give more insight than
standard statistical analyses.47
Three considerations affect the CV of a PG test: the degree to which predicted risks fits
observed data (calibration); the ability of the test to separate those who are truly at risk from
those who are not (discrimination); and change in risk assignment compared with no testing
(reclassification). These considerations are prerequisites to evaluating CU (see later).
Calibration assesses whether predicted risks from models that include genetic variants and
other factors are correct.48,49 Calibration is especially important when models have untested
or incorrect assumptions (e.g., independent, multiplicative effects; no interactions; and
applying effect sizes obtained from various studies to the tested population).
Discrimination assesses the overlap in risk distributions of people who will develop the disease
and those who will not. For good discrimination, a broad distribution of risks is required. The
area under the curve (AUC) is one measure of the discriminative ability of a test.50–53 It is
generated by plotting all sensitivity–specificity combinations for all possible cut-off values of
the predicted risks. Because of small effect sizes, most genetic variants included in the current
genome profiles have low discriminative accuracy and contribute only marginally to AUC
compared with existing risk factors.54–56 Many more genetic variants are needed to increase
the discriminative ability and predictive value of PG.57,58
Reclassification refers to the proportion of persons who change risk categories when prediction
models are updated to incorporate new genetic variants. If risk categories are defined according
to cut points used to indicate type or intensity of interventions, reclassification can impact
clinical management (see discussion of clinical utility later). However, if individuals do not
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change risk categories, as a result of adding genetic information, reclassification will not be
clinically useful. One has to consider also the number of individuals who are in risk categories
where reclassification would make a difference. Studies with few such individuals (e.g., where
all persons have low risk, far from the cut-off where reclassification would influence decision
making) may not be able to arrive at robust estimates of the extent and correctness of
reclassification. Analyses of the AUC should be integrated with analyses of risk reclassification
to maximize information on the use of new markers for risk prediction.59,60 The evidence on
risk reclassification based on the genetic markers is rapidly growing. For example, the
association of a variant on chromosome 9p21.3 (rs10757274) with cardiovascular disease has
been extensively replicated but has been shown to be a significant risk classifier for future
cardiovascular disease in some studies but not in others.61–64
Establishing clinical utility in personal genomics
CU is a measure of the net health benefits of PG tests (benefits minus harms). The cumulative
assessment of CU and the level of certainty associated with the assessment depend on the
clinical scenarios under consideration.65 CU evaluation should follow principles of
comparative effectiveness research.66 The CU of PG tests may be evaluated for their ability to
improve outcomes when either added to or substituting current approaches. For example, what
kinds of nongenetic interventions could serve as adequate benchmarks for genomic information
to be compared; and what study designs would be needed to assess the impact of PG tests on
health care resources—e.g., resources for case management for those found to have increased
risk? For any particular scenario, the balance of benefits and harms will depend on the factors
such as the predictive value of genomic information, the availability and performance measures
of other risk assessment tools, the acceptability, cost and efficacy of proven interventions to
reduce risk, and possibly other factors such as potential stigmatization as well perceived
personal value of the information. These issues are discussed in the population screening
literature.12
Some suggest considering the “personal utility” of PG, in which genetic and other health
information may be useful to individuals even in the absence of effective interventions. For
example, in a series of publications from the Risk Evaluation and Education for Alzheimer
disease study (the REVEAL Study), Green and coworkers67–71 have evaluated different
methods for communicating genetic information to people at risk of Alzheimer Disease (AD).
Even though there are no proven effective interventions to remediate risk, the results of these
studies indicate that some people perceived this information to be useful by allowing them to
prepare their families and arrange personal affairs including long-term care. Moreover, those
who opted for testing did not generally experience adverse psychological effects from test
results provided as part of a genetic counseling protocol, even when they learned they were at
high risk for AD.
In evaluating the role of personal utility, it will be crucial to develop appropriate metrics to
consider the impact of different indices of individual perceived value of personalized genomics
on health-related benefits, costs, and harms associated with testing and interventions, both to
individuals and the society at large.72 Finally, the impact of personal utility on appropriate use
of health care resources will have to be further explored.
Direct and indirect evidence of clinical utility: When do we need clinical trials?
There is much to learn about how genetically guided risk reclassification can improve health
outcomes. Well-calibrated models that can reclassify people into higher risk groups that require
different interventions may provide indirect evidence of CU but these have been rarely
available in the PG field. However, we must also consider how such reclassification, especially
with small changes in risks due to small effect sizes affects the need to change interventions
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(e.g., cholesterol lowering drugs or screening for cancer detection), and how such changes can
alter the balance of benefits and risks, as well as the economic implications of testing. There
is also the possibility of frequent risk reclassification based on the additional genetic variants,
as demonstrated in a prospective population-based study of Type 2 diabetes risk using 18
genetic variants in addition to age, sex, and body mass index (Janssens, personal
communication, 2009). The utility of learning about risk updates must be considered and its
impact assessed, particularly when lifestyle and nutrition recommendations and medical
decisions can vary accordingly.
An unresolved question is whether observational studies can provide sufficient CU information
without randomized clinical trials (RCTs). Lord et al.73 argue that CV studies suffice to show
CU if a new diagnostic test is safer or more specific than, but of similar sensitivity to, an old
test. However, if a new test is more sensitive than an old test, it can lead to the detection of
additional cases of disease (often milder or earlier onset). Results from the treatment trials that
enroll only patients detected by the old test may not apply to these extra cases. RCTs may be
needed, unless we can be satisfied that the new test detects the same spectrum and subtype of
disease as the old test and that intervention response is similar across the spectrum of disease.
Hypotheses for CU often come from biological and clinical data suggesting that response to
interventions (e.g., pharmacogenomics) may work differently for population groups.74,75 The
question is whether this information will translate into net health benefits in practice.76 To
assess the CU of genetic tests, the EGAPP working group has developed analytic frameworks
similar to those developed by the USPSTF, with key questions to frame the evidence; clear
definitions of clinical and other outcomes of interest; explicit search strategies; use of
hierarchies to characterize data sources and study designs; quality assessment of individual
studies, synthetic assessment of all available evidence, linkage of evidence to
recommendations; and avoidance of conflicts of interest.15 For most genomic applications (and
many other diagnostic tests), direct evidence about the effectiveness and value of testing is
rarely available from RCTs. For recent evaluations, the group has constructed a chain of
evidence linking the strength of the association between a genotype and disorder of interest
(CV) to evidence that test results can change intervention decisions and improve net health
benefits (CU). So far, the group has tackled genomic applications in symptomatic patients and
their families rather than the asymptomatic population at large, the main target group for PG,
although similar chains of causal reasoning and evidence synthesis can be applied. For
example, based on the biological reasoning, CYP450 testing was proposed as a test for adults
with nonpsychotic depression before treatment with selective serotonin reuptake inhibitors.
The EGAPP Working Group reviewed evidence for validity and utility of testing and found
that CYP450 genotypes were not consistently associated with clinical response to selective
serotonin reuptake inhibitor treatment or adverse events, and that no clinical trials had been
conducted to evaluate benefits and harms. Thus, CYP450 testing was not recommended for
this clinical situation.16 Another example is genetic testing to inform anticoagulation therapy
with warfarin. The CYP2C9 and VKORC1 genes are implicated in warfarin and vitamin K
metabolism, and variants in these genes are consistently associated with warfarin bleeding
complications. Without large, well-designed clinical trials, however, it is not known if
genotyping to determine warfarin dosing could reduce adverse consequences of hemorrhage
or thrombosis or could improve health outcomes such as reduced rates of hospitalization or
mortality.77 Recently, the International Warfarin Pharmacogenetics Consortium developed an
algorithm for estimating warfarin dose based on both clinical and genetic data from a broad
population cohort study.78,79 In evaluating CU, economic issues also should be considered.
For example, Eckman et al.80 concluded that warfarin-related genotyping is unlikely to be cost
effective for typical patients with atrial fibrillation (marginal cost effectiveness exceeded $170
000 per quality-adjusted life year). However, testing for warfarin dosing may be cost effective
in patients at high risk for hemorrhage.80 Economic models that include sensitivity analyses
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need to be revisited frequently given the declining prices of PG tests and the rapid rise in health
care costs.
RCTs can be used to develop direct evidence for CU of PG in relation to both behavioral and
pharmacological interventions. RCTs could be used to identify subgroups of individuals based
on the PG profiles where interventions are most effective and to apply intervention only in
those subgroups. RCTs also could be used to identify subgroups of individuals based on the
PG profiles with side effects, so that reduced dosages or alternative interventions can be used.
Even if no differences in the effects of interventions exist by genotype, RCTs can be used to
assess whether genotype-based interventions can be more effective overall if they improve
adherence to available interventions that are designed for the general population.
Examples of research questions amenable to RCTs are given in Table 2. RCTs have rarely been
conducted to assess the CU of genetic information in changing behavior. Studies that have
examined health behavior change have generally found that genetic risk information by itself
is insufficient to promote complex behavior changes such as smoking cessation and alteration
of dietary and exercise habits (see later). However, an emerging body of evidence suggests
that genetic risk information may increase preferences for biological interventions over health
behavior changes when both are viable options.81 For example, some studies82–84 have
suggested that individuals presented with genetic risk information are more likely to affirm the
importance of pharmaceutical treatments for conditions like heart disease and depression over
lifestyle change or psychotherapy. In the REVEAL study, where no proven treatments are
available to prevent AD participants learning that they were APOEe4+ were more likely than
their APOEe4− counterparts to report engagement in suspected but not proven AD risk
reduction activities (e.g., vitamin E71). The potential for both health benefits and harms of these
activities needs to be evaluated.
An example of an ongoing RCT is a primary care-based study to assess the CU of TCF7L2
testing for Type 2 diabetes in altering behavior and health measures in prediabetic patients
(Ginsburg, personal communication). Secondary goals are to measure whether changes in
perceived risk and beliefs about genetics are associated with behavior change after genetic
testing and to determine whether a genetics-guided clinical trial would change primary care
physicians' beliefs and understanding of genetics and their role in practice, especially vis-à-vis
existing approaches to diabetes control that do not use genetic information.
The behavioral and social research dimensions of clinical utility
Behavioral research conducted to date on the CU of genetic information has focused largely
on the potential of genetic information to increase perceptions of vulnerability to adverse health
outcomes. A considerable literature exists around genetic testing for rare hereditary cancers.
85,86 Usually, persons considering genetic testing for rare genetic disorders want to know what
tests are offered, what the results might mean for themselves and their families, what
information they will have access to, where they can go for more information, and whether
any of the information is actionable and whether action can lead to improved outcomes.
In considering PG tests, the target group is mostly asymptomatic people in the population.87,
88 With relatively high innumeracy levels, education and awareness are critical for decision
making by providers and consumers. Traditionally, mass media approaches have been used to
increase awareness of health issues.89 However, emerging technologies now offer new
approaches to personalized communication. For example, health communication with tailored
health messages sent to mobile phones can be useful in conveying information about alcohol-
related risks.90 In theory, educational approaches could be tailored not only to individual
demographics, psychosocial beliefs, abilities, and preferences but also to genomic information.
However, to date, rigorous evaluations of these technologies have been infrequent. Research
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is needed to develop effective and context-based approaches to communicate genetic
information to promote comprehension of genetic information, informed decision making
about testing and adopting healthy behaviors. Such research will need to incorporate best
practices from the risk communication literature on how to emphasize actionable health
messages from those that are inconclusive or potentially misleading.91,92
Early studies evaluating the use of single gene variants to convey personalized risks for lung
cancer to cigarette smokers have shown no benefit for smoking cessation.93,94 McBride et al.
8 are evaluating a prototypic “multiplex” genetic susceptibility test similar to those marketed
DTC. The goal of this project is to evaluate the characteristics of individuals who are most
interested in such testing and whether the information provided by PG can spur individuals to
seek additional risk assessments (e.g., family history and behavioral risk assessments) and/or
additional health services (e.g., well care visits). Although the multiplex study does not directly
involve measurement of health outcomes, it will provide valuable information on social and
psychological differences between those who opt to be tested versus those who decline testing,
whether individuals who opt for such testing are able to accurately interpret their test results,
whether interpretation of test results is associated with positive or negative emotions or changes
in risk perception, and whether PG test results lead individuals to seek other personal health
risk information.8 Another opportunity in this line of research is determining whether
participants communicate such test results to their primary care providers and if so, how this
information impacts service delivery in primary care. Some have expressed concern that an
unintended consequence of the DTC model may be “raiding the medical commons,” as
consumers who are encouraged to “ask their doctor” may bring PG test information to providers
who are unequipped to interpret the information, which consumes time and resources, may
take away from preventive services of established value, and may result in ordering
unwarranted procedures or interventions.5
As we consider the potential utility of PG, we must use a multidisciplinary approach that moves
beyond the focus on the psychological effects of risk communication to understand the value
of PG in behavioral change. Existing but limited public health interventions, such as promoting
energy balance to prevent obesity, have not been completely effective at the population level.
Clinical trials evaluating weight loss interventions consistently show high attrition rates
because individuals have difficulty adhering to recommendations for energy balance.95 It is
unclear, but crucial to learn, whether PG information could be used to tailor interventions that
promote weight loss.96 PG information also may enable us to further deconstruct behavioral
phenotypes to identify and measure pathways that influence health behaviors. In turn, this
information could offer new behavioral targets for intervention.
Recommendations for establishing the scientific foundation for personal
genomics
Workshop participants made five broad recommendations to enhance the scientific foundation
for using PG as a tool for improving health. Specific areas of discussion are also published
online.9
Develop and implement scientific standards for personal genomics
Several companies are collaborating in developing standards for PG tests. This work should
be expanded to include transparent criteria for analytic standards, clinical standards on
selection of genetic variants with high credibility, use of appropriate data to interpret reported
allelic odds ratios in terms of overall risk compared with appropriate reference populations,
and model calibration and evaluation of risk distributions for health conditions included in PG
tests. The current statement from three companies represented at the workshop is available.
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40 In addition, standards for evaluating the CV and utility of PG tests need to be developed by
independent panels (see fourth recommendation below).
Develop and implement a multidisciplinary research agenda
Multiple scientific disciplines are needed to develop the PG field (Table 3). In addition to
biological studies that can point to therapeutic and preventive interventions, epidemiologic
studies are needed for risk characterization, especially of gene–gene and gene–environment
interactions. Study cohorts must be quite large to have adequate statistical power.97 Clinical
and population studies using communication, behavioral, and social sciences are needed across
the translation continuum to assess the effectiveness of genetic information for consumers and
providers. We need a robust health services research agenda that includes dissemination
research to assess the uptake of evidence-based practice into routine care and outcomes
research to improve the quality and effectiveness of health services. Also, we need public health
surveillance and assessment of cost effectiveness and impact on health disparities. Current
federal genomic initiatives in translation research98–103 should be enhanced. New models of
translation research should be explored such as current collaborations among industry,
academia, consumers, and government.104
Enhance credible knowledge synthesis and dissemination of information to providers and
consumers
Timely cumulative knowledge synthesis, based on standardized formats and systematic,
evidence-based processes, is needed to summarize and update information on genetic
associations and to document their CV and CU. Such information needs to be translated in an
accessible fashion and disseminated to consumers, providers, and policy makers to inform
decision making. Given the rapid pace of discovery in the PG field, new mechanisms may be
needed to provide rapid turnaround of evidence reviews, to keep all stakeholders current
relative to the best available data. This will require enhanced public and provider education.
Link scientific research on validity and utility to evidence-based recommendations for use
of personal genomic tests
The evidence threshold for implementing personal genomic information into clinical practice
and disease prevention must be considered by independent panels that have no conflict of
interest and use rigorous systematic evaluations. The current dilemma is that setting the
evidence bar fairly low allows diffusion of genomic discoveries in practice, before there is
adequate information on CV and CU. Consequently, payers may not cover testing costs.
Conversely, setting the evidence bar too high may result in tests with high validity and utility
but with lower financial incentive for innovation by developers. Paradoxically, this could lead
to fewer developed tests and potentially diminished health benefits from PG tests.105 Because
PG tests potentially affect a large number of asymptomatic persons in the population, extra
caution is needed to establish appropriate evidentiary thresholds. Such screening tests can
expose large numbers of healthy people to potential harms from false-positive results (such as
anxiety and “labeling,” as well as additional invasive testing and treatment) or from false-
negative results (such as false reassurance and attendant lapses in personalized risk factor
reduction efforts). As a result, independent groups formulating evidence-based clinical
recommendations such as the USPSTF have required a high level of certainty that the benefits
of screening outweigh the harms and therefore have set a high evidence bar for recommending
preventive services. To achieve an appropriate linkage between evidence and practice,
independent panels such as EGAPP and USPSTF should provide rapid and timely assessments
to determine in a systematic and transparent fashion whether a PG test and its associated
interventions does more good than harm in specific population groups or on a population-wide
basis. In preventive services, the USPSTF has had a major role for more than three decades
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and has conducted formal analyses of hundreds of preventive interventions. The task force has
generally set a high evidentiary bar for preventive tests used in asymptomatic populations.
EGAPP has recently established methods and processes for genomic-related applications. The
field of PG will greatly benefit from such independent evaluations.
Consider the value of personal utility
Finally, as discussed earlier, we should continue to explore individuals' and population
subgroups' notions of perceived personal utility of PG (e.g., advantages of learning about
genomic risk) and to assess whether personal utility may impact measures of CU (e.g., via
improved adherence to recommendations). However, these perceptions of utility will need to
be considered in the context of broader societal costs. In order for personal utility to be
scientifically supported, objective metrics must be developed and applied in rigorous
multidisciplinary observational studies and RCTs. These metrics should include measurable
benefits, harms, as well as costs of PG testing and interventions.
In conclusion, to make the best use of PG for improved health outcomes, the CV and CU of
these tests must be understood by consumers, providers, and policy makers. Scientific
standards for evaluating these tests must be established and a mechanism put in place to provide
authoritative, unbiased, timely reviews of new discoveries. Clinical, epidemiologic,
communication, behavioral, social, and economic studies of PG must be rigorously pursued.
Finally, these scientific standards have to be examined in the context of principles of population
screening with full consideration of the ethical, legal and social, economic, and policy issues.
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Table 1
Potential uses of personal genomics to improve health, in relation to stages of disease
prevention and therapya
Potential use of personal genomics to improve
health Description Examples
Primary prevention Testing that leads to reduction of disease
incidence
Testing for susceptibility to cancer, type 2
diabetes, coronary heart disease to target
interventions (e.g., cholesterol reduction,
weight loss, chemoprevention)
Secondary prevention Testing that leads to early disease detection
and interventions
Testing for susceptibility to prostate cancer,
and colorectal cancer (e.g., targeted
screening)
Tertiary prevention Testing that leads to personalized treatments
(e.g., pharmacogenomics)
Testing for susceptibility to drag reactions
and effectiveness (e.g., warfarin, SSRIs)
Quaternary prevention Testing that leads to patients' improved quality
of life, psychosocial effects, palliative care,
etc.
Testing for susceptibility to diseases, with no
available interventions (e.g., Alzheimer
disease)
a
There are other terminologies used for stages of prevention (e.g., primordial prevention in heart disease). The stages presented here apply to cancer
and other common chronic diseases and are elaborated on by Miller et al.11
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Table 2
Examples of research questions in personal genomics that can be addressed in randomized
controlled trialsa
1 Do health outcomes from medical or lifestyle interventions compared with a control group differ among genetic subgroups?
2 Do health outcomes from specific medications compared with the control medication or placebo differ among genetic subgroups?
3 What are the health outcomes from a specific intervention or treatment, in a specific high-risk genetic subgroup, compared with a
control intervention or usual care?
4 What is the efficacy of a genetically based treatment approach (e.g., adjusting drag dose based on genetic information) compared with
a standard clinical approach?
5 What health behavior changes and/or psychosocial outcomes result from differing approaches to risk communication?
6 Does providing patients with information about their genetic risk result in improved adherence to prescribed behaviors or medications?
7 What are the best approaches for genetic risk communication and informed decision making in genetic testing?
8 Does provision of DTC PG testing influence health care service demand and delivery, especially in primary care?
a
Some of the questions can be addressed using existing RCTs.
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Table 3
Multidisciplinary research needed for evaluating personal genomics to improve health and
prevent disease
Field Scientific research Current issues
Epidemiology Genotype prevalence, calculating risks
associated with genetic variants, gene–gene,
and gene environment interactions
Data currently lacking on magnitudes of
risks especially for joint effects of genes
and environment
Clinical evaluation Quantify added value of personal genomics in
reclassifying risks compared traditional risk
factors
Data currently suggest weak
discriminatory ability of personal
genomics compared with other factors. It
is not yet clear what are the net health
benefits versus harms in using personal
genomics in prevention and clinical care
Behavioral and social sciences Assess how genome profiles affect behavior of
individuals, families and populations
Data from other fields suggest that
behavior change is difficult. It is not clear
if genome information matters
Communication sciences Study communication and education
strategies for using genomic information to
improve health
Provider and consumers are not equipped
to deal with this type of information
Health services research & Public health
surveillance
Assess impact of genome info health outcomes
in the real world, health disparities, and
economic indicators
Expensive technology when applied in
populations; unknown health benefits and
potential harms
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